HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
VALENCIA, Calif., Jan. 27, 2016 -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 3, 2016.
Presenting from the Company will be its Chief Executive Officer, Matthew Pfeffer and Chief Medical Officer, Raymond Urbanski.
To view and listen to the webcast, visit MannKind’s website at http://www.mannkindcorp.com and click on the “MannKind 2/3/16 Conference Call” link in the Webcast section of News & Events. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 41729996. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4172 9996#. A replay will also be available on MannKind's website for 14 days.
As with past calls, the Company will take live questions from covering analysts. However, departing slightly from past practice for this call, stockholders who wish to submit questions in advance of the call should email them to [email protected].
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact:
Matthew J. Pfeffer
Chief Executive Officer
661-775-5300
[email protected]
